HCM
HALO icon

Highbridge Capital Management’s Halozyme HALO Stock Holding History

Highbridge Capital Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-153,900
Closed -$1.46M – 1524
2016
Q1 		$1.46M Buy
+153,900
New +$1.45M 0.02% 609

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's HALO Position: Q1 2017 in Review

Highbridge Capital Management sold out of Halozyme (HALO) in Q1 2017, closing a stake of 21,770 shares — an estimated $215K sold.

Highbridge Capital Management first reported a position in HALO in Q2 2013 and held it in 3 quarters. The position peaked at $629K in Q3 2015. 160 funds tracked by Wall St. Rank hold HALO as of Q1 2017.

  • Highbridge Capital Management reported no remaining Halozyme position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 21,770 Halozyme shares in Q1 2017, an estimated $215K.
  • Highbridge Capital Management first reported a position in Halozyme in Q2 2013 and held it in 3 quarters.
  • Highbridge Capital Management's Halozyme position peaked at $629K in Q3 2015.
  • 160 funds tracked by Wall St. Rank held Halozyme as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.